Cyclin-Dependent Kinase (CDK) Panel Screening Service
We provide a comprehensive Cyclin-Dependent Kinase (CDK) Panel Screening Service to support investigations into cell cycle control and its role in disease. This service includes a variety of assays focused on key CDK proteins, enabling evaluation of their activity, expression, and response to potential inhibitors. Leveraging advanced technologies and in-depth analysis, we deliver actionable insights to drive research in cancer, developmental biology, and other fields where CDKs are critically involved. Our aim is to contribute to your scientific progress with results that are accurate, dependable, and delivered on time.
Service Background
Cyclin-dependent kinases (CDKs) are key regulators of the cell cycle and are involved in essential cellular functions such as proliferation, differentiation, and apoptosis. Through phosphorylation of target proteins, CDKs, in partnership with cyclins, drive cell cycle progression. Aberrant CDK activity is closely associated with a variety of diseases, particularly cancer, making them prominent targets in drug development. Our CDK Panel Screening Service offers a robust, high-throughput platform for assessing CDK activity and inhibition across diverse experimental models.
Fig.1 The cell cycle phases and their associated cyclin-dependent kinases (CDK)/cyclin complexes.1
Cyclin-Dependent Kinase (CDK) Panel Screening Service at Creative Biolabs
We offer:
Our CDK Panel Screening Service offers a broad range of assays to assess the inhibition and activity of multiple CDK isoforms, including but not limited to:
- CDK1 – A key regulator of the G2/M transition in the cell cycle.
- CDK2 – Essential for the G1/S transition and DNA replication.
- G1 phase regulators and essential for cell cycle progression include CDK4 and CDK6.
- A part of the CDK-activating kinase (CAK) complex, CDK7 plays a crucial role in transcription and cell cycle control.
- CDK9: Contributes to RNA polymerase II's transcriptional elongation.
We provide both activity assays (to measure the kinase activity) and inhibition assays (to test potential inhibitors) for each CDK in the panel. Additionally, we offer detailed data analysis, including IC50 calculations, enzyme kinetics, and the profiling of compound effects.
Service process:
Why Choose Us
- Comprehensive Panel: Our service includes screening for a wide range of CDK isoforms, allowing you to assess multiple targets simultaneously.
- High-Throughput Capacity: Our advanced screening technologies enable the testing of large compound libraries, ensuring efficiency and scalability.
- Customizable Assays: Tailor the assays to your specific needs, including different substrates, inhibitors, or screening conditions.
- Detailed Data Reporting: We provide in-depth reports that include potency analysis, dose-response curves, and IC50 values, allowing for actionable insights.
- Expert Consultation: Our team of experts provides personalized support and guidance throughout the screening process to ensure your research objectives are met.
Frequently Asked Questions
A1: What CDK isoforms are included in the screening panel?
Q1: Our panel includes the most commonly studied CDKs such as CDK1, CDK2, CDK4, CDK6, CDK7, and CDK9. Additional isoforms can be included upon request.
A2: Can I screen my compound library with your service?
Q2: Yes, we can screen your library of compounds, natural products, or synthetic molecules against the CDK panel. Custom compounds can be tested as part of the service.
A3: What assay formats do you offer?
Q3: We offer a variety of assay formats including luminescence, fluorescence, and colorimetric assays, which can be tailored to suit your needs.
Contact Us
Please get in touch with us to discuss your unique needs or to learn more about our Cyclin-Dependent Kinase Panel Screening Service. Our team is ready to assist you in advancing your research or drug development projects. We look forward to partnering with you in your scientific discovery!
Reference
- García-Reyes, Balbina et al. "The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma." International journal of molecular sciences vol. 19,10 3219. Distributed under Open Access license CC BY 4.0, without modification.
Download our brochure